Cambridge science and technology cluster leads trade fightback
Cambridge Cluster science & technology companies have started the fightback against a virtual UK lockdown with global deals and strategies collectively worth billions.
Arm’s Japanese parent SoftBank has led the way by kickstarting the sale of $41bn worth of assets in a bid to restore former glories. AstraZeneca is investing £80 million in a new therapeutics play from its Cambridge HQ.
Abcam and AVEVA are back on the acquisition trail, with Abcam’s expansion in America spearheading a string of new trade deals between East of England businesses and the US.
A cohort of local companies are part of £multimillion projects to provide vaccines, diagnostic tests, sanitants and a battery of weapons to help the UK conquer the coronavirus, COVID-19. And amid it all comes ingenuity to burn. Redgate Software is using the home working period to launch a new coding club for children.
Also, Business Weekly unveils a 12-strong pantheon of ‘Super Scalers’ – companies in our TTP-sponsored Killer50 list of the hottest science & technology companies in the region who are scaling to fresh heights from already dizzy plateaus.
All this and more – including top quoted companies’ latest results and news of a new breed of spinouts and startups – is in a 42-page special digital edition of Business Weekly available to access FREE on this site today.
It shows just how strong the cluster is proving in adversity – and why our companies are attracting so much attention, even now, from global investors and collaborators.
Doors at physical offices may be closed but windows of opportunity for fresh trade have been left ajar to keep UK and cross-border trade ticking over nicely.
To access the digital edition visit https://bit.ly/2Jlmatz